McKesson (MCK) Aktievy
McKesson Corporation tillhandahåller hälsovårdstjänster i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 0/6 |
Last Earnings Call
Q1 2027 · 5 Aug 2026Executive Summary
McKesson (NYSE: MCK) reported strong Q1 fiscal 2027 results, with revenue rising 8% to $105.4 billion and adjusted earnings per diluted share (EPS) increasing 20% to $9.93. Performance was driven by double-digit operating profit growth in three core segments: North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions. Key drivers included steady healthcare utilization, specialty medication volume growth, and disciplined expense management. Management raised its full-year adjusted EPS guidance to $44.20–$45.00.
Financial Performance vs. Consensus
- Revenue: Actual revenue of $105.4 billion beat the analyst consensus estimate of $103.2 billion 1, 2.
- Adjusted EPS: Actual EPS of $9.93 beat the analyst consensus estimate of $9.15 1, 2.
Market Reaction
McKesson shares rose approximately 4.5% in after-hours trading on August 5, 2026. Analysts attributed the positive movement to the company’s strong earnings beat, upward guidance revision, and sustained momentum across its specialty and oncology segments, which helped offset concerns regarding branded pharmaceutical pricing dynamics.
Sources: 1 McKesson Q1 Fiscal 2027 Earnings Release (Aug 05, 2026) 2 Bloomberg/FactSet Analyst Consensus Data (Retrieved Aug 05, 2026)
MCK Community Fair Values
Create NarrativeSee what 104 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
McKesson Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$869.58 |
| 52 veckors högsta | US$999.00 |
| 52 veckors lägsta | US$637.00 |
| Beta | 0.31 |
| 1 månads förändring | 6.22% |
| 3 månaders förändring | 18.14% |
| 1 års förändring | 30.06% |
| 3 års förändring | 97.60% |
| 5 års förändring | 338.23% |
| Förändring sedan börsintroduktionen | 5,170.18% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 06
MCK: Biosimilar Co Manufacturing Optionality Will Drive Future Defensive Haven Appeal
McKesson's analyst fair value estimate has been raised from $941.40 to $980.80 as analysts factor in higher Street price targets and updated models that reference recent quarterly results, peer multiple moves, and shifting assumptions on long term P/E and profitability. Analyst Commentary Recent Street research on McKesson points to a mixed but generally constructive view on valuation and execution, with several firms revising price targets following quarterly updates and changes in sector assumptions.Seeking Alpha • Jul 08
McKesson Checks All The Boxes To Survive And Prosper In A Weak Economy, But There's A Big Catch
Summary McKesson is highlighted as a stable portfolio holding with regular moderate growth amid a challenging, overvalued market environment. A major correction could impact MCK alongside the broader market. Despite broad market risks, I seek to maximize results by selectively holding resilient stocks like MCK. Strategic positioning may limit damage in a bear market, and this article uses MCK as a case study for navigating potential downturns. Most future articles on individual stocks may need to consider the potential impact of AI on the stock and its industry. Companies that are "middlemen" in a "distributor" business like MCK may be particularly vulnerable to competition from agentic AI, which is faster, cheaper, and equally effective. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Aug 06
MCK: Biosimilar Co Manufacturing Optionality Will Drive Future Defensive Haven Appeal
McKesson's analyst fair value estimate has been raised from $941.40 to $980.80 as analysts factor in higher Street price targets and updated models that reference recent quarterly results, peer multiple moves, and shifting assumptions on long term P/E and profitability. Analyst Commentary Recent Street research on McKesson points to a mixed but generally constructive view on valuation and execution, with several firms revising price targets following quarterly updates and changes in sector assumptions.Seeking Alpha • Jul 08
McKesson Checks All The Boxes To Survive And Prosper In A Weak Economy, But There's A Big Catch
Summary McKesson is highlighted as a stable portfolio holding with regular moderate growth amid a challenging, overvalued market environment. A major correction could impact MCK alongside the broader market. Despite broad market risks, I seek to maximize results by selectively holding resilient stocks like MCK. Strategic positioning may limit damage in a bear market, and this article uses MCK as a case study for navigating potential downturns. Most future articles on individual stocks may need to consider the potential impact of AI on the stock and its industry. Companies that are "middlemen" in a "distributor" business like MCK may be particularly vulnerable to competition from agentic AI, which is faster, cheaper, and equally effective. Read the full article on Seeking AlphaUppdatering av berättelse • Jun 25
MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Haven Appeal
McKesson's analyst price target has been trimmed to $941 from $950, reflecting analysts' slightly more conservative assumptions around policy, biosimilar, and GLP-1 uncertainties, while still incorporating potential long-term benefits from areas such as biosimilar co-manufacturing. Analyst Commentary Recent Street research on McKesson points to a mixed but engaged view of the stock, with several firms revising price targets and reassessing assumptions around policy risk, biosimilars, and GLP 1 exposure.Analysartikel • Jun 17
McKesson (MCK) Stock Could Be 17.3% Undervalued After Loan Deal And Buybacks
McKesson (MCK) stock is in focus after a cluster of recent moves, including a US$2.25b senior secured term loan maturing in 2032, a minority sale in Medical-Surgical Solutions and ongoing share repurchases. See our latest analysis for McKesson. After a weaker quarter and a pullback that left the 90 day share price return down 14.66% and the year to date share price return down 4.62%, McKesson still has a 1 year total shareholder return of 8.87% and a very large 5 year total shareholder...Uppdatering av berättelse • Jun 06
MCK: Medical Surgical Spin Off And Biosimilar Manufacturing Will Shape Future Haven Appeal
McKesson's analyst price target has been trimmed by about $2 to $949.73 as analysts recalibrate their fair value and future P/E assumptions following a recent cluster of target cuts and one increase across major research firms. Analyst Commentary Bullish Takeaways Bullish analysts have recently lifted their targets in some cases, suggesting they still see upside potential relative to current execution and long term growth initiatives.Uppdatering av berättelse • May 13
MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal
Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.Analysartikel • May 11
McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...Uppdatering av berättelse • Apr 27
MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal
McKesson's analyst price target has been trimmed slightly, with the fair value estimate edging down by about $1 to $990.87 as analysts factor in recent target cuts alongside ongoing interest in the company's biosimilar and distribution opportunities. Analyst Commentary Recent research on McKesson has centered on how much value the market is assigning to its biosimilar pipeline, distribution scale and perceived defensiveness within healthcare, with a mix of higher and lower price targets reflecting different views on execution risk and current valuation.Uppdatering av berättelse • Apr 10
MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Safe Haven Appeal
McKesson's analyst-derived fair value estimate has been adjusted slightly lower, from about $997.67 to $991.67. Analysts are weighing recent trims to Street price targets and fresh caution around premium valuation against prior enthusiasm for biosimilar optionality and healthcare defensiveness.Uppdatering av berättelse • Mar 27
MCK: Biosimilar And Co Manufacturing Upside Will Shape Future Safe Haven Returns
Analysts have nudged the McKesson fair value estimate slightly higher to about $998, citing a wave of Street price target increases into the $1,040 to $1,050 range and growing focus on potential upside from biosimilars and co-manufacturing. Analyst Commentary Recent Street research around McKesson clusters around two themes: valuation and execution on new growth levers such as biosimilars and co-manufacturing.Uppdatering av berättelse • Mar 11
MCK: Biosimilar Optionality And Premium Safe Haven Position Will Shape Future Returns
Analysts have increased their McKesson price target from $980.40 to $995.27, citing higher Street targets that reflect new biosimilar optionality and continued interest in the stock as a perceived healthcare safe haven, even at a premium valuation. Analyst Commentary Bullish analysts are leaning into McKesson's role as a perceived healthcare safe haven and the new biosimilar angle, using these themes to justify higher valuation levels than the recent three year average.Uppdatering av berättelse • Feb 24
MCK: Defensive Healthcare Premium And Buybacks Will Shape Perceived Safety Trade
Analysts have raised McKesson's fair value estimate by about $14 to $980.40, as a series of higher Street price targets, including Barclays' move to $1,050, keeps the stock in focus for investors seeking perceived safety within healthcare, even as shares trade at a premium to recent averages. Analyst Commentary Recent research has centered on McKesson's valuation after a series of price target increases, including a move to US$1,050 that highlights how closely investors are watching the name as a perceived defensive healthcare holding.Uppdatering av berättelse • Feb 09
MCK: Refined Assumptions And Supportive Policy Backdrop Will Shape FY26 AOI
The McKesson analyst price target has been raised by about $24 to $966, with analysts pointing to updated fair value work, modest adjustments to the discount rate and growth assumptions, and slightly higher future P/E expectations as key drivers of the change. Analyst Commentary Recent Street research on McKesson clusters around higher price targets and refreshed valuation work, with analysts fine tuning assumptions on growth, discount rates and future P/E multiples.Uppdatering av berättelse • Jan 26
MCK: North American Pharma Momentum And Supportive Policy Backdrop Will Drive FY26 AOI
Narrative Update The analyst price target for McKesson has been raised by roughly $3 to $942.00, as analysts point to steady assumptions for revenue growth, margins and P/E, along with supportive views on North American Pharma momentum, a constructive industry demand backdrop, and the absence of new onerous proposals in recent healthcare policy commentary. Analyst Commentary Recent research on McKesson is broadly constructive, with several firms lifting their price targets and pointing to supportive sector trends and company specific drivers.Uppdatering av berättelse • Jan 12
MCK: North American Pharma Strength Will Support FY26 Core AOI Framework
Narrative Update: McKesson Analysts have lifted their McKesson price targets toward a range of about $900 to $1,000, citing solid North American Pharma momentum, modeled core AOI growth of around 7% for FY26, and a robust demand backdrop reflected in peers' recent results. Analyst Commentary Recent research updates reflect a more constructive stance on McKesson, with higher price targets tied to underlying business trends and peer readthroughs rather than short term trading factors.Uppdatering av berättelse • Dec 18
MCK: North American Pharma Momentum Will Drive Future EPS Framework Confidence
Our McKesson narrative fair value has increased modestly to approximately $939 per share from about $935, reflecting analysts' higher price targets and conviction in sustained EPS growth, improved North American Pharma momentum, and a more robust valuation framework supported by stronger industry demand trends. Analyst Commentary Street research sentiment on McKesson remains skewed positive, with a broad wave of price target increases reflecting higher conviction in the companys ability to deliver on its upgraded long term earnings framework and FY26 guidance.Uppdatering av berättelse • Dec 03
MCK: North American Pharma Momentum Will Drive Future Outlook Amid Policy Uncertainty
We modestly raise our McKesson fair value estimate to about $934.79 per share from roughly $934.71, reflecting analysts' higher price targets, stronger confidence in long term EPS growth, and sustained North American Pharma momentum. Analyst Commentary Street research on McKesson has turned increasingly constructive, with multiple firms lifting price targets in response to upgraded long term guidance, stronger segment momentum, and enhanced disclosure following the recent investor day.Uppdatering av berättelse • Nov 19
MCK: Future Execution and Pharma Trends Will Shape Outlook Amid Policy Uncertainty
McKesson's analyst price target has been raised significantly, increasing by nearly $90 per share to $934.71. Analysts cite strong momentum in North American Pharma, higher long-term EPS guidance, and robust industry trends supporting continued growth.Uppdatering av berättelse • Nov 05
MCK: Future Demand and Oncology Distribution Will Set the Earnings Outlook
McKesson’s analyst price target has increased from approximately $837 to $845. Analysts cite robust demand, industry-wide utilization trends, and the company’s strengthened long-term earnings outlook as key factors supporting the upward revision.Uppdatering av berättelse • Oct 22
Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments
Analysts have raised their average fair value estimate for McKesson to $836.71 from $829.57. This change is attributed to increased long-term growth guidance and improved business visibility following the company’s recent investor day.Uppdatering av berättelse • Oct 08
Pharmaceutical Demand And Digital Automation Will Shape Future Markets
McKesson's analyst fair value estimate has been raised from $793.21 to $829.57. This increase reflects higher price targets, driven by analysts who cite upgraded long-term growth guidance and strengthened expectations following recent investor presentations.Uppdatering av berättelse • Sep 24
Pharmaceutical Demand And Digital Automation Will Shape Future Markets
McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21. What's in the News Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.Seeking Alpha • Mar 25
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
Summary I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily. Despite potential tariff-related risks in the biotech sector, McKesson's strong performance and strategic guidance make it a safe haven for investors in 2025. Read the full article on Seeking AlphaSeeking Alpha • Jan 21
McKesson Seems Cheap, But Risks Linger
Summary McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow, despite recent price increases and solid growth prospects in oncology and GLP-1 medications. Quarterly results show mixed performance, with revenue up 21.3% YoY but operating income and EPS down; adjusted EPS grew 13.5% YoY. Risks include political pressures on drug pricing, competition from vertically integrated healthcare providers like CVS and Amazon, and potential recession impacts. Despite bullish arguments and recession resilience, I rate McKesson as a 'Hold' due to high recession risk and a cautious market outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Summary I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers. Future growth driven by GLP-1 medications, oncology network expansion, and margin improvements, despite weak growth in Medical surgical solutions post-Covid. Read the full article on Seeking AlphaSeeking Alpha • Oct 09
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Summary Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock is giving investors a nice entry point as it reverts to the mean S&P500 returns. The company was the highest-scoring large cap on the most recent Magic Formula screen for October 2024. The Healthcare distribution sub-sector provides exposure to big Pharma without the patent cliffs. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
McKesson: The Correction Is Not Over
Summary McKesson declined about 20% in the last few weeks and sentiment suddenly turned. Of course, McKesson is performing hand-in-hand with the overall market and we can expect that McKesson will continue to decline - similar to the overall market. On the other hand, we can argue that McKesson is already undervalued a bit, but I still think the stock will continue to decline further due to the overall sentiment. Read the full article on Seeking AlphaAktieägarnas avkastning
| MCK | US Healthcare | US Marknad | |
|---|---|---|---|
| 7D | 1.6% | -0.3% | 4.0% |
| 1Y | 30.1% | 40.5% | 20.7% |
Avkastning vs industri: MCK presterade sämre än US Healthcare branschen som gav 40.5 % under det senaste året.
Avkastning vs Marknaden: MCK översteg US marknaden som gav 20.7 % under det senaste året.
Prisvolatilitet
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 4.3% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: MCK har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: MCK s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1833 | 42,300 | Brian Tyler | www.mckesson.com |
McKesson Corporation tillhandahåller hälso- och sjukvårdstjänster i USA och internationellt. Verksamheten bedrivs genom fyra segment: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions och Medical-Surgical Solutions. Företaget distribuerar märkes-, generiska-, special-, biosimilar- och receptfria läkemedel samt andra sjukvårdsrelaterade produkter, levererar produkter till detaljhandelsapotek, sjukhus, långtidsvårdcentraler, kliniker och institutioner samt tillhandahåller logistik- och distributionstjänster för tillverkare.
McKesson Corporation Sammanfattning av grunderna
| MCK grundläggande statistik | |
|---|---|
| Börsvärde | US$101.59b |
| Vinst(TTM) | US$4.59b |
| Intäkter(TTM) | US$410.98b |
22.1x
P/E-förhållande0.2x
P/S-förhållandeÄr MCK övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MCK resultaträkning (TTM) | |
|---|---|
| Intäkter | US$410.98b |
| Kostnad för intäkter | US$396.05b |
| Bruttovinst | US$14.93b |
| Övriga kostnader | US$10.34b |
| Intäkter | US$4.59b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 39.39 |
| Bruttomarginal | 3.63% |
| Nettovinstmarginal | 1.12% |
| Skuld/egenkapitalförhållande | -742.5% |
Hur har MCK utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.4%
Aktuell utdelningsavkastning9%
UtbetalningskvotGer MCK en tillförlitlig utdelning?
Se MCK utdelningshistorik och jämförelsetal| McKesson datum för utdelning | |
|---|---|
| Ex utdelningsdag | Sep 01 2026 |
| Utbetalningsdag för utdelning | Oct 01 2026 |
| Dagar till Ex-utdelning | 24 days |
| Dagar till utdelningsdag | 54 days |
Ger MCK en tillförlitlig utdelning?
Se MCK utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/07 08:15 |
| Aktiekurs vid dagens slut | 2026/08/07 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
McKesson Corporation bevakas av 33 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |